SEC Form 4 · accession 0001193125-26-340173
Attovia Therapeutics, Inc. · ATTO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sanofi
10% Owner
Period of report
Aug 6, 2026
Accepted (ET)
Aug 7, 2026 · 3:45 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002058707
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F3 | Aug 6, 2026 | C | 782,855 | — | A | 782,855 | I | See footnote |
| Common StockF2,F3 | Aug 6, 2026 | P | 300,000 | $17.00 | A | 1,082,855 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series C Preferred StockF1,F3 | — | Aug 6, 2026 | C | 782,855 | D | — | — | Common Stock | 782,855 | 0 | I |
Explanation of responses
- F1The Series C preferred stock (the "Preferred Stock") converted by its terms in full automatically into shares of common stock, upon the consummation of the Issuer's initial public offering (the "IPO") on August 6, 2026. The convertibility and expiration of the Preferred Stock prior to the IPO are described in Sanofi's Form 3, filed with the Securities and Exchange Commission on August 4, 2026.
- F2Represents a purchase in the Issuer's IPO.
- F3Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries.
Remarks
Immediately upon consummation of the IPO, Sanofi's beneficial ownership of the common stock fell below 10%, as a result of the issuance of additional shares of common stock.